To the best of our knowledge, this is the first detailed study covering the importance of Irf-3 during the treatment of osteoclast-related diseases, extending the possibility of applying Hes to target Irf-3 in other osteoclastic diseases such as cancer bone metastasis, osteoarthritis, bacterial infection and wear-particle-induced calvarial osteolysis. This evidence concerns the gene IRF3 and bacterial infectious disease.